The verdict's in: citizens are the solution

Silversides, Ann
July 2008
CMAJ: Canadian Medical Association Journal;7/15/2008, Vol. 179 Issue 2, p132
Academic Journal
The article reports on the Citizens' Council which will provide advice to Helen Stevenson $3.5 billion public drug plan. Ontario's new council is a part of larger trend in developed countries to involve more members of the public and patient groups in the health care system. It tackles a broader range of public health care issues, not just drug policy and reports to the National Institute for Health and Clinical Excellence, an arm's length body that advises the National Health services. To look at specific issues, similar bodies have been convened in Canada, such as the Citizens Assembly on Electoral Reform in British Columbia or a Public Health Agency of Canada. The Citizens' Council will be the first ongoing all-citizen council advising a provincial drug plan. INSET: Britain's experience: gardeners and students made a difference.


Related Articles

  • NICE has a huge role to play in pharma comms.  // PRWeek (London);2/1/2008, p19 

    The article presents the views of Pam Bourne of Packer Forbes on the role of the National Institute for Health and Clinical Excellence (NICE) of Great Britain in pharmaceutical companies. Bourne relates the media exposure of NICE in line with drug approval stories. Louise Fish, communications...

  • 150 public health QOF points loom. Davies, Madlen // Pulse;9/12/2012, Vol. 72 Issue 29, p3 

    The article reports that the British National Institute for Health & Clinical Excellence (NICE) has been asked about the introduction of a new public health domain in 2013 QOF, as part of moves to ring-fence 150 points for preventing diseaseby the ministers.

  • Europe's Health Sector Pushes Review of New Therapies' Value. Moran, Nuala // BioWorld International;12/14/2011, Vol. 16 Issue 50, p1 

    The article reports on the collaboration of the healthcare sector in Europe to push for industry involvement in the health technology assessments (HTA) that are being performed to measure the added-value of therapies and used as the basis of deciding whether or not to pay for them. A joint...

  • Health technology assessment under scrutiny. Jessop, Nathan // Pharmaceutical Technology Europe;Sep2011, Vol. 23 Issue 9, p22 

    The article discusses the management of expensive treatments by healthcare technology assessment (HTA), a multidisciplinary field of policy analysis. As stated, Great Britain's HTA the National Institute for Health and Clinical Excellence has caused frustration to the pharmaceutical industry in...

  • NICE Guide to the Methods of Technology Appraisal: Pharmaceutical Industry Perspective. Earnshaw, Julia; Lewis, Gavin // PharmacoEconomics;2008, Vol. 26 Issue 9, p725 

    The article highlights the "Guide to the Methods of Technology Appraisal" developed by the National Institute for Health and Clinical Excellence (NICE) in England. It explores the challenges and key considerations in updating the guide, as well as the recommended methods in choosing the...

  • Pharmaceutical industry braced for "value based" drug pricing. Hawkes, Nigel // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/5/2010, Vol. 340 Issue 7758, p1216 

    The article focuses on the plan of the British government to reform the drug pricing strategy in Great Britain. The government plans to implement a value-based pricing method called Pharmaceutical Price Regulation Scheme, which is expected to strengthen the power of the National Institute for...

  • NICE should follow example of Scottish Medicines Consortium. Cornell, S. John // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/21/2009, p430 

    No abstract available.

  • The future role of NICE: Value based pricing does not remove the need for rigorous analysis of the cost effectiveness of new drugs. Maynard, Alan; Bloor, Karen // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;11/13/2010, Vol. 341 Issue 7781, p1006 

    The authors ponder on the possible consequences from the plans to eliminate the National Institute for Health and Clinical Excellence (NICE) of Great Britain its authority to make decisions on drug rationing in 2010. They contend that relationship between doctors and drug manufacturers has...

  • Court rules that NICE procedure on dementia drugs was unfair. Dyer, Clare // BMJ: British Medical Journal (International Edition);5/10/2008, Vol. 336 Issue 7652, p1035 

    The article focuses on a 2008 judgment from a British appeals court which was concerned with the medical care of dementia patients. In the judgment the court ruled that a key step which had been used by Great Britain's National Institute for Health and Clinical Excellence in the process for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics